Applied Biosystems Completes Equity Investment in VisiGen
News Dec 12, 2005
Concurrent with its investment, Applied Biosystems also entered into a scientific collaboration agreement with VisiGen.
The VisiGen investment is part of Applied Biosystems’ strategy of maintaining its position in DNA sequencing by complementing its internal investments in new and existing sequencing technologies with promising next-generation approaches.
VisiGen’s technological approach to DNA sequencing is based on the ability to analyze a single molecule of DNA in real-time.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE